TNFRII-Ig (BioPremiere)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameTNFRII-Ig (BioPremiere)
Drug Alias Nametetravalent TNF receptor II-Ig fusion protein (BioPremiere)
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunoglobulin agonistsTumor necrosis factor receptor superfamily member 1B agonists
TargetsImmunoglobulinTumor necrosis factor receptor superfamily member 1B
Therapy Area/IndicationsInflammationImmune System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBioPremiere Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBioPremiere Inc
Active IndicationsN/A
Inactive IndicationsInflammationImmune System Diseases

Other Information

ATC CodeN/A
Related LinksN/A